We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Odds still favor Novartis heart failure drug Serelaxin.
- Authors
Ratner, Mark
- Abstract
The article focuses on the rejection of an investigational drug Serelaxin manufactured by the pharmaceutical firm Novartis, by the U.S. Food and Drug Administration (FDA) after the controversies related to the confounding trial of the drug. It mentions the positive response in favor of the drug after the phase 3 clinical trial of the drug, which shows the effectiveness in the treatment of acute heart failure. It also mentions the benefit of the drug in the measurement of dyspnea.
- Subjects
UNITED States. Food &; Drug Administration; NOVARTIS AG; HEART failure; DYSPNEA; CLINICAL trials
- Publication
Nature Biotechnology, 2014, Vol 32, Issue 7, p602
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0714-602